How much weight loss does retatrutide cause in trials?

The TRIUMPH-1 Results

TRIUMPH-1, the primary Phase 3 trial in adults without diabetes, reported these results at 48 weeks:

• Retatrutide 12 mg: 24.2% mean body weight loss
• Retatrutide 8 mg: 17.5% mean body weight loss
• Retatrutide 4 mg: 12.3% mean body weight loss
• Placebo: 2.1% mean body weight loss

Results in Context

Historical comparisons

• Semaglutide 2.4 mg (STEP 1, 68 weeks): 14.9%
• Tirzepatide 15 mg (SURMOUNT-1, 72 weeks): 22.5%
• Retatrutide 12 mg (TRIUMPH-1, 48 weeks): 24.2%

Retatrutide achieved greater weight loss in less time than previous class drugs — a significant advance.

Real-world implications

For a 250 lb patient:

• Retatrutide 12 mg: expected ~60 lbs loss
• Tirzepatide 15 mg: expected ~56 lbs loss
• Semaglutide 2.4 mg: expected ~37 lbs loss

Responder Rate Distribution

TRIUMPH-1 reported the following proportion of participants achieving significant weight loss:

12 mg arm

• ≥ 5% weight loss: 96%
• ≥ 10% weight loss: 89%
• ≥ 15% weight loss: 75%
• ≥ 20% weight loss: 56%
• ≥ 25% weight loss: 35%

8 mg arm

• ≥ 5% weight loss: 87%
• ≥ 10% weight loss: 72%
• ≥ 15% weight loss: 50%
• ≥ 20% weight loss: 27%

4 mg arm

• ≥ 5% weight loss: 72%
• ≥ 10% weight loss: 45%
• ≥ 15% weight loss: 25%

Timeline of Weight Loss

Weeks 1–16 (titration phase)

• Steady initial loss during titration
• Approximately 8–12% weight loss by week 16 at highest dose arm
• Early and rapid results appeared

Weeks 16–32 (early maintenance)

• Continued loss at max dose
• Approximately 18–20% weight loss by week 32 at highest dose arm
• Loss rate slows but remains significant

Weeks 32–48 (late maintenance)

• Further loss continuing
• Final 24% weight loss at week 48
• Suggests continued losses beyond trial endpoint if extended

Secondary Outcomes

Metabolic improvements

• HbA1c reduction of ~2% in diabetic patients
• Blood pressure reduction (12 mg: -8 mmHg systolic)
• Triglycerides reduction ~20%
• LDL cholesterol moderate reduction
• HDL moderate increase

Body composition

• DEXA data showed meaningful fat reduction
• Lean mass loss proportional to total loss (~25–30%)
• Visceral fat particularly affected

Cardiovascular markers

• Reduction in inflammation markers (CRP)
• Favorable changes in lipid profile
• Longer-term CV outcomes trial ongoing

Why Retatrutide Produces More Weight Loss

Triple receptor agonism

• GLP-1 receptor: appetite suppression, delayed gastric emptying, insulin sensitization
• GIP receptor: additional appetite effects, metabolic sensitization
• Glucagon receptor: increased hepatic lipolysis, energy expenditure

The glucagon receptor activation is the key additional mechanism not present in semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP). It increases baseline energy expenditure and promotes fat utilization — adding a "burn" component to the "eat less" effect of GLP-1 class drugs.

Subgroup Analysis

Women vs men

• Similar relative weight loss
• Women had slightly greater body composition improvements

Higher BMI patients

• Greater absolute weight loss (more to lose)
• Similar relative percentage

Older vs younger patients

• Similar weight loss across age groups
• No age-related responsiveness differences

What About Weight Loss Plateau?

Trial data suggest retatrutide users may not plateau as quickly as semaglutide or tirzepatide users:

• Loss continued at 48 weeks at max dose
• Extended trial will provide 72+ week data
• Plateau expected eventually — not immune to biological adaptation

Comparison to Bariatric Surgery

• Gastric bypass: 25–35% total weight loss, 12–24 months
• Retatrutide 12 mg: 24% at 48 weeks
• Difference: retatrutide approaches but doesn't quite match surgical results — while being reversible and non-invasive

Maintaining the Weight Loss

TRIUMPH data suggest retatrutide will face similar regain issues as other GLP-1 class drugs when stopped. No extended cessation data yet available, but stopping any of these drugs has consistently shown substantial regain.

Real-World Expectations

• Trial participants are selected (motivated, adherent)
• Real-world weight loss typically ~70–80% of trial values
• Expect ~18–20% real-world loss at 12 mg (vs 24% in trial)
• Individual variation is significant

Limitations of Current Data

• 48 weeks is relatively short for a chronic medication
• Long-term safety and efficacy data still accumulating
• Phase 4 post-marketing experience will provide more information
• Head-to-head trials vs tirzepatide planned

Bottom Line

Retatrutide produces the most weight loss of any approved or near-approved anti-obesity medication — 24% mean at 12 mg over 48 weeks. This represents a meaningful advance over tirzepatide and semaglutide. Expect real-world results somewhat lower than trial values but still class-leading.

See the retatrutide guide. Related: vs tirzepatide, dosage protocol.